Stay updated on Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial page.

Latest updates to the Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe Locations section now includes a new Illinois site. The HHS Vulnerability Disclosure link was removed and the page revision updated to v3.3.3.SummaryDifference0.2%

- Check18 days agoNo Change Detected
- Check25 days agoNo Change Detected
- Check32 days agoChange DetectedRevision: v3.3.2 has been added and Revision: v3.3.1 has been removed.SummaryDifference0.0%

- Check39 days agoChange DetectedRevision tag updated from v3.2.0 to v3.3.1; no changes to trial details, outcomes, eligibility criteria, or locations.SummaryDifference0.0%

- Check46 days agoChange DetectedThe funding status notice about government operations was removed from the page. This notice previously warned that updates may be delayed due to appropriations.SummaryDifference0.2%

- Check61 days agoChange DetectedNo additions or deletions affecting core page content were detected; the study overview and eligibility details appear unchanged.SummaryDifference0.2%

- Check89 days agoChange DetectedMajor update to core content with a funding-status notice and a version upgrade from v3.0.2 to v3.2.0.SummaryDifference3%

Stay in the know with updates to Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial page.